Companies in #Hyperphagia
Found 1 company operating in this sector.
Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapeutics that activate innate homeostatic pathways — including bitter taste receptors (TAS2R) — to treat metabolic and inflammatory disease. Its lead candidate ARD-101 targets hyperphagia in Prader-Willi syndrome; the Phase 3 HERO trial was voluntarily paused in February 2026 and terminated, and the FDA lifted its clinical hold in October 2026, leaving the programme awaiting a redesigned Phase 3 and a lower-dose resumption. A second programme, ARD-201, is in development for obesity.